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“A multimorbidity lens creates exciting opportunities to reconceptualise health and wellbeing in 
all its complexity. We need to improve health metrics to capture this complexity and strengthen 
health services to respond to it.”
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The ‘diseases of affluence’ model was turned upside down in the 1990s by the recognition that the burden 
of cardiovascular disease, diabetes, chronic respiratory disease, cancer and other chronic non-communicable 
diseases (NCDs) was not just high in high-income countries (HICs); 80% of the global NCD burden was in 
low- and middle-income countries (LMICs) [1]. This neglect of NCDs has delayed prioritisation and allocation 
of resources (human, financial and infrastructural) to biomedical research, training of health professionals 
and healthcare [2], leaving the poorest countries with the greatest need with the greatest gaps in care and 
in data. 
Today, multimorbidity faces the problem single NCDs faced three decades ago: a global problem but barely 
recognised where it is likely to be most prevalent, and least researched in the settings where least is known. 
Multimorbidity, the ‘existence of multiple medical conditions in a single individual’ [3], has the person, not 
a disease, as the focus, but is still a comparatively underused term in literature and practice, with variable 
definitions. As with NCDs, the gap between multimorbidity burden and level of awareness, prevention and 
treatment necessary to avert the rising human, financial and healthcare costs in all countries is increasingly 
recognised, particularly in LMICs. Multimorbidity is not just for the West. In this sense, LMICs and their 
health systems have unique opportunities to leapfrog advances in healthcare delivery by not replicating the 
same structures of healthcare established in HICs. We explore this on three fronts, data, human resources, 
and care guidelines, whilst acknowledging progress (how to) in each aspect requires multisectoral support.
First, data for monitoring and accountability are required, since multimorbidity-related data remain lim-
ited [3]. Rather than generating disease-specific data, LMICs (and HICs) can move forward to generate a 
wider multimorbidity-based picture, in order to understand the most common clusters of multimorbidity 
and mainly those linked to higher morbidity [4], i.e. quality of life and patient burden [5], and mortality, 
based on specific disease burdens in certain geographical regions. The advantage of this approach would not 
only be in the understanding of conditions, but also in forming the basis of the design of the most prom-
ising interventions for research and implementation, together with the evaluation of patient-important 
outcomes [5–6].
Second, training of human resources. Improving services alone will not suffice without adequate training 
of the next generation of the health workforce. The existing crisis of human resources for health worldwide 
signals to the ‘elephant in the room’: we cannot afford to train health professionals into single-disease 
specialists [7]. This does not mean that specialists are not needed. On the contrary, we need generalists 
and specialists to better organise care such that specialist advice is available to greater numbers of people 
in community settings. This prioritisation does also provide further support to the call for universal health 
coverage [8].
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Third, in terms of care, NICE has been at the forefront of producing guidelines for the management of 
multimorbidity [9]. The NICE multimorbidity guideline covers clinical assessment and management, and 
makes recommendations for research around organisation of care, holistic community assessment, polyp-
harmacy and de-prescribing, and better prediction of life expectancy. This was developed in the UK context 
and to what degree this guidance is applicable, in part or in full, to LMICs remains to be explored and will 
vary by setting. So far, with few exceptions, most notably around HIV services [10], disease-centred and frag-
mented health services are more common in LMICs. 
Whilst there may be many considerations beyond data, human resources and disease guidelines, LMICs 
should adapt sooner, faster and better to accommodate responses to multimorbidity rather than disease-
specific structures. This is consistent with strengthening primary health care and universal health coverage 
via its contribution to high-quality healthcare [8]. These changes would be timely as they address conditions 
across the range of physical and mental non-communicable and communicable diseases [3–4], particularly 
as evidence grows to show that multimorbidity increases mortality in coronavirus (COVID-19) infection [11].
Indeed, multimorbidity creates an opportunity to re-conceptualise health and the lived experience of 
health and multiple conditions in ways that are likely to differ substantially from clinical ideas and medi-
calised views of wellbeing. Disease-focused, medicalised concepts of health sometimes neglect the com-
plex social, financial and labour burdens of living with multiple chronic health conditions. Disease-specific 
actions vary, ranging from physical rehabilitation to timely medication adherence to modifying behaviours 
in terms of diet and physical activity, and emphasis is often placed on self-management and self-monitoring. 
But the complexities of actions and concepts of individuality and self are incompatible with the home and 
community environment where living with and managing multimorbidity takes place. Measures of multi-
morbidity need to describe wellbeing in this social context and strategies of community engagement and 
mobilisation are needed to ready and empower, not just individuals, but whole communities for coping with 
multimorbidity. Models of community mobilisation have shown promise in relation to a number of health 
outcomes in LMICs, and are likely to be particularly effective when combined with strengthening of data 
systems, and supply-side provision of quality, integrated care.
Addressing multimorbidity will be a challenge, a major one but necessary and long overdue. As our popu-
lations survive longer with multiple disease burdens over their lifetimes, more humane, high-quality, and 
long-term interactions with health services are required. Multimorbidity is the litmus test for the future of 
health and the experience of health, healthcare, and above all, the wellbeing of everybody, not only patients 
and caregivers, but also providers. There have been multiple attempts to better bridge the gap between 
simple intervention trials and the reality and complexity of implementation in real-world settings, e.g. the 
UK Medical Research Council complex intervention framework [12]. In health informatics, the prominence 
of continuously collected and utilised electronic health data in ‘science’, ‘evidence’ and ‘care’ is growing in 
the ‘learning health system’ model. The lens of multimorbidity may represent the best way of integrating 
various approaches across research, practice and implementation. 
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